These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22684378)

  • 1. Forget Mars and venus, men and women are from the same planet after all.
    Parikh PB; Gruberg L
    J Invasive Cardiol; 2012 Jun; 24(6):261-2. PubMed ID: 22684378
    [No Abstract]   [Full Text] [Related]  

  • 2. Gender differences in patients treated with the zotarolimus-eluting stent at a tertiary medical center.
    Shammas NW; Shammas GA; Lemke J; Miller S; Meriner S
    J Invasive Cardiol; 2012 Jun; 24(6):256-60. PubMed ID: 22684377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Angiographic restenosis and clinical recurrence after sirolimus- and paclitaxel-eluting stent implantation.
    Vlaar PJ; Zijlstra F
    JACC Cardiovasc Interv; 2009 Aug; 2(8):776-8. PubMed ID: 19695547
    [No Abstract]   [Full Text] [Related]  

  • 5. Gender medicine and drug eluting coronary stents.
    Kornowski R
    Catheter Cardiovasc Interv; 2010 Nov; 76(6):814-6. PubMed ID: 21104730
    [No Abstract]   [Full Text] [Related]  

  • 6. Long-term clinical and angiographic outcomes of diabetic patients after revascularization with early generation drug-eluting stents.
    Billinger M; Räber L; Hitz S; Stefanini GG; Pilgrim T; Stettler C; Zanchin T; Pulver C; Pfäffli N; Eberli F; Meier B; Kalesan B; Jüni P; Windecker S
    Am Heart J; 2012 May; 163(5):876-886.e2. PubMed ID: 22607867
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Residual Stenosis on the Angiographic Edge Restenosis of a Second-Generation Drug-Eluting Stent.
    Kozuma K; Shinozaki T; Kozuma K; Kashiwabara K; Oba K; Aoki J; Awata M; Nanasato M; Shiode N; Tanabe K; Yamaguchi J; Kimura T; Matsuyama Y
    Int Heart J; 2019 Sep; 60(5):1050-1060. PubMed ID: 31484868
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Five-year clinical outcomes of a polymer-free sirolimus-eluting stent versus a permanent polymer paclitaxel-eluting stent: final results of the intracoronary stenting and angiographic restenosis - test equivalence between two drug-eluting stents (ISAR-TEST) trial.
    King L; Byrne RA; Mehilli J; Schömig A; Kastrati A; Pache J
    Catheter Cardiovasc Interv; 2013 Jan; 81(1):E23-8. PubMed ID: 22431239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview.
    Goyal BK; Kalmath BC; Kawar R; Sharma A; Khemnar B; Rangnekar H
    Indian Heart J; 2013 Dec; 65(6):678-82. PubMed ID: 24407537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions.
    Ruef J; Störger H; Schwarz F; Haase J
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):333-9. PubMed ID: 18288747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of limus-eluting stents and balloon angioplasty for sirolimus-eluting in-stent restenosis.
    Ota H; Mahmoudi M; Kitabata H; Torguson R; Chen F; Satler LF; Suddath WO; Pichard AD; Waksman R
    Cardiovasc Revasc Med; 2015 Mar; 16(2):84-9. PubMed ID: 25870152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Late target lesion revascularization following drug-eluting stents - looking back and forward to success.
    Moliterno DJ
    Catheter Cardiovasc Interv; 2008 Feb; 71(3):304-5. PubMed ID: 18288752
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of early versus late clopidogrel discontinuation on stent thrombosis following percutaneous coronary intervention with first- and second-generation drug-eluting stents.
    Loh JP; Torguson R; Pendyala LK; Omar A; Chen F; Satler LF; Pichard AD; Waksman R
    Am J Cardiol; 2014 Jun; 113(12):1968-76. PubMed ID: 24767975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized clinical study comparing double kissing crush with provisional stenting for treatment of coronary bifurcation lesions: results from the DKCRUSH-II (Double Kissing Crush versus Provisional Stenting Technique for Treatment of Coronary Bifurcation Lesions) trial.
    Chen SL; Santoso T; Zhang JJ; Ye F; Xu YW; Fu Q; Kan J; Paiboon C; Zhou Y; Ding SQ; Kwan TW
    J Am Coll Cardiol; 2011 Feb; 57(8):914-20. PubMed ID: 21329837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sex-specific outcomes following revascularization with zotarolimus-eluting stents: comparison of angiographic and late-term clinical results.
    Brown RA; Williams M; Barker CM; Mauri L; Meredith IT; Fajadet J; Wijns W; Leon MB; Kandzari DE
    Catheter Cardiovasc Interv; 2010 Nov; 76(6):804-13. PubMed ID: 20815043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
    Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elutax paclitaxel-eluting balloon followed by bare-metal stent compared with Xience V drug-eluting stent in the treatment of de novo coronary stenosis: a randomized trial.
    Liistro F; Porto I; Angioli P; Grotti S; Ducci K; Falsini G; Bolognese L
    Am Heart J; 2013 Nov; 166(5):920-6. PubMed ID: 24176449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Outcomes After Treatment with ELCA for In-Stent Restenosis of DES.
    Nakamura F; Amaki T; Fukino K
    Int Heart J; 2018; 59(1):1-2. PubMed ID: 29375109
    [No Abstract]   [Full Text] [Related]  

  • 19. Impact of body mass index on long-term clinical outcomes after second-generation drug eluting stent implantation: Insights from the international global RESOLUTE program.
    Diletti R; Garcia-Garcia HM; Bourantas C; Van Mieghem NM; van Geuns RJ; Muramatsu T; Zhang YJ; Mauri L; Belardi J; Silber S; Widimsky P; Leon M; Windecker S; Meredith I; Neumann FJ; Yeung AC; Saito S; Liu M; van Leeuwen F; Serruys PW
    Catheter Cardiovasc Interv; 2015 May; 85(6):952-8. PubMed ID: 25689692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular responses to the multiple overlapped paclitaxel-eluting stents for the treatment of bare-metal in-stent restenotic lesions: angiographic and intravascular ultrasound analysis from the TAXUS-V ISR trial.
    Koizumi T; Fitzgerald PJ; Honda Y; Ellis SG; Kent K; Martin SL; Brown CL; Masud AR; Patterson JB; Greenberg J; Friedman M; Uchida T; Stone GW
    Cardiovasc Revasc Med; 2010; 11(3):140-8. PubMed ID: 20599163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.